A global company developing and manufacturing advanced laser systems for medical and aesthetic applications. An R&D-driven specialist providing diverse laser solutions for skin disease treatment and aesthetic improvement.Aglobalcompanydevelopingandmanufacturingadvancedlasersystemsformedicalandaestheticapplications.AnR&D-drivenspecialistprovidingdiverselasersolutionsforskindiseasetreatmentandaestheticimprovement.
Key Products/TechnologiesKeyProducts/Technologies
PicoLO Nd: YAG Laser: A picosecond laser system utilizing dual wavelengths of 1064nm and 532nm. Effective for pigmented lesion and tattoo removal, scar correction, and skin rejuvenation with ultra-short picosecond pulses and high stability. Features proprietary DOE (Diffractive Optical Element) fractional technology to induce LIOB (Laser Induced Optical Breakdown) even at low fluence. The upgraded PicoLO Premium model offers a larger spot size for faster treatments and a Dia FX handpiece for multi-layer skin targeting.PicoLONd:YAGLaser:Apicosecondlasersystemutilizingdualwavelengthsof1064nmand532nm.Effectiveforpigmentedlesionandtattooremoval,scarcorrection,andskinrejuvenationwithultra-shortpicosecondpulsesandhighstability.FeaturesproprietaryDOE(DiffractiveOpticalElement)fractionaltechnologytoinduceLIOB(LaserInducedOpticalBreakdown)evenatlowfluence.TheupgradedPicoLOPremiummodeloffersalargerspotsizeforfastertreatmentsandaDiaFXhandpieceformulti-layerskintargeting.
HELIOS Ⅲ Nd: YAG Laser: A Q-switched Nd:YAG laser system with dual wavelengths of 1064nm and 532nm. Its uniform beam pattern reduces side effects such as hyperpigmentation and hypopigmentation. Incorporates RTP (Real Twin Pulse) technology to consistently deliver two identical pulses, minimizing pain and enhancing treatment comfort. Provides various treatment modes and zoom, collimator, and fractional handpieces for customized treatment plans.HELIOSⅢNd:YAGLaser:AQ-switchedNd:YAGlasersystemwithdualwavelengthsof1064nmand532nm.Itsuniformbeampatternreducessideeffectssuchashyperpigmentationandhypopigmentation.IncorporatesRTP(RealTwinPulse)technologytoconsistentlydelivertwoidenticalpulses,minimizingpainandenhancingtreatmentcomfort.Providesvarioustreatmentmodesandzoom,collimator,andfractionalhandpiecesforcustomizedtreatmentplans.
LOTUS Ⅲ ER: YAG Laser: An innovative multi-pulsed Er:YAG laser system with a 2940nm wavelength. Capable of ablating various epidermal lesions with a 40us cold ablation mode and coagulating tissue with a 5ms ultra-long pulse mode. Utilizes fractional and zoom handpieces for treating diverse skin conditions, offering minimal downtime and discomfort.LOTUSⅢER:YAGLaser:Aninnovativemulti-pulsedEr:YAGlasersystemwitha2940nmwavelength.Capableofablatingvariousepidermallesionswitha40uscoldablationmodeandcoagulatingtissuewitha5msultra-longpulsemode.Utilizesfractionalandzoomhandpiecesfortreatingdiverseskinconditions,offeringminimaldowntimeanddiscomfort.
PALLAS UV Laser: The world's first solid-state 311nm/308nm UV (Narrow Band UVB) laser system. Uses Titanium Sapphire (Ti:Sapphire) as the laser medium, providing stable output without consumables or toxic gas, an eco-friendly technology. Features a collimator handpiece adjustable from 1mm to 12mm for selective treatment based on lesion size. The PALLAS Premium model is an upgraded version with improved pulse repetition rate and spot size for faster treatments.PALLASUVLaser:Theworld'sfirstsolid-state311nm/308nmUV(NarrowBandUVB)lasersystem.UsesTitaniumSapphire(Ti:Sapphire)asthelasermedium,providingstableoutputwithoutconsumablesortoxicgas,aneco-friendlytechnology.Featuresacollimatorhandpieceadjustablefrom1mmto12mmforselectivetreatmentbasedonlesionsize.ThePALLASPremiummodelisanupgradedversionwithimprovedpulserepetitionrateandspotsizeforfastertreatments.
ZELOS Alexandrite Laser: A product line utilizing Alexandrite laser technology, applicable for various dermatological procedures.ZELOSAlexandriteLaser:AproductlineutilizingAlexandritelasertechnology,applicableforvariousdermatologicalprocedures.
HYPERION ND: YAG Laser: A product line applying Nd:YAG laser technology, used in specific medical and aesthetic fields.HYPERIONND:YAGLaser:AproductlineapplyingNd:YAGlasertechnology,usedinspecificmedicalandaestheticfields.
Core AdvantagesCoreAdvantages
Core Component Design Capabilities: Possesses proprietary core component design and in-house manufacturing capabilities for resonators, ultra-short pulse width, power supply design, wavelength conversion, and energy amplification, based on original laser technology. This ensures technological superiority and cost competitiveness.CoreComponentDesignCapabilities:Possessesproprietarycorecomponentdesignandin-housemanufacturingcapabilitiesforresonators,ultra-shortpulsewidth,powersupplydesign,wavelengthconversion,andenergyamplification,basedonoriginallasertechnology.Thisensurestechnologicalsuperiorityandcostcompetitiveness.
World's First Solid-State UV Laser Development: Commercialized the world's first solid-state 311nm/308nm UV laser 'PALLAS' without toxic gas, ensuring stable output, reducing maintenance costs, and enhancing patient safety. This innovative technology overcomes the limitations of existing gas-based excimer lasers.World'sFirstSolid-StateUVLaserDevelopment:Commercializedtheworld'sfirstsolid-state311nm/308nmUVlaser'PALLAS'withouttoxicgas,ensuringstableoutput,reducingmaintenancecosts,andenhancingpatientsafety.Thisinnovativetechnologyovercomesthelimitationsofexistinggas-basedexcimerlasers.
Proprietary Technology Acquisition: Offers differentiated treatment effects and patient convenience through unique laser technologies such as PicoLO's DOE fractional technology and HELIOS III's RTP (Real Twin Pulse) technology. The stable energy output and pulse duration of its picosecond lasers are superior to many competitor products.ProprietaryTechnologyAcquisition:OffersdifferentiatedtreatmenteffectsandpatientconveniencethroughuniquelasertechnologiessuchasPicoLO'sDOEfractionaltechnologyandHELIOSIII'sRTP(RealTwinPulse)technology.Thestableenergyoutputandpulsedurationofitspicosecondlasersaresuperiortomanycompetitorproducts.
Global Market Approvals and Network: Obtained major country approvals including US FDA, European CE, Japanese PMDA, and Brazilian ANVISA, and was the first Korean laser company to pass MDSAP certification, exporting products to over 50 countries worldwide. Leverages its Asia-Pacific network to expand into new markets in North America, Europe, and the Middle East.GlobalMarketApprovalsandNetwork:ObtainedmajorcountryapprovalsincludingUSFDA,EuropeanCE,JapanesePMDA,andBrazilianANVISA,andwasthefirstKoreanlasercompanytopassMDSAPcertification,exportingproductstoover50countriesworldwide.LeveragesitsAsia-PacificnetworktoexpandintonewmarketsinNorthAmerica,Europe,andtheMiddleEast.
Continuous R&D Investment and Product Line Expansion: Establishes a diverse product lineup from aesthetic to disease treatment, with ongoing R&D investments for new market entry, including vascular lesion, skin lifting, and urinary stone treatment devices. Demonstrates market responsiveness through upgrades and new product launches like HELIOS IV 785, PicoLO Premium, and PALLAS Premium.ContinuousR&DInvestmentandProductLineExpansion:Establishesadiverseproductlineupfromaesthetictodiseasetreatment,withongoingR&Dinvestmentsfornewmarketentry,includingvascularlesion,skinlifting,andurinarystonetreatmentdevices.DemonstratesmarketresponsivenessthroughupgradesandnewproductlauncheslikeHELIOSIV785,PicoLOPremium,andPALLASPremium.
High Export Ratio and Growth Trajectory: Exports accounted for over 69% of total revenue in Q3 2023, with a compound annual growth rate (CAGR) of 58.65% from 2020 to 2022, indicating rapid growth. Achieves continuous export performance, including the '20 Million Dollar Export Tower' award, strengthening its position in the global market.HighExportRatioandGrowthTrajectory:Exportsaccountedforover69%oftotalrevenueinQ32023,withacompoundannualgrowthrate(CAGR)of58.65%from2020to2022,indicatingrapidgrowth.Achievescontinuousexportperformance,includingthe'20MillionDollarExportTower'award,strengtheningitspositionintheglobalmarket.
Target IndustrieTargetIndustrie
Medical Aesthetics Industry: Various aesthetic procedures such as treatment of pigmented lesions (melasma, freckles, age spots, Nevus of Ota-like macules), tattoo removal, skin rejuvenation and lifting, acne scar improvement, pore reduction, wrinkle improvement, skin elasticity enhancement, carbon peel, hair bleaching, and lip rejuvenation.MedicalAestheticsIndustry:Variousaestheticproceduressuchastreatmentofpigmentedlesions(melasma,freckles,agespots,NevusofOta-likemacules),tattooremoval,skinrejuvenationandlifting,acnescarimprovement,porereduction,wrinkleimprovement,skinelasticityenhancement,carbonpeel,hairbleaching,andliprejuvenation.
Industrial Laser Sector: Initial history of developing and producing semiconductors, industrial CO2 lasers, and industrial laser heads.IndustrialLaserSector:Initialhistoryofdevelopingandproducingsemiconductors,industrialCO2lasers,andindustriallaserheads.
Major MarketsMajorMarkets
South Korea, Japan, Singapore, Taiwan, various Asia-Pacific countriesSouthKorea,Japan,Singapore,Taiwan,variousAsia-Pacificcountries
various European countriesvariousEuropeancountries
United States, CanadaUnitedStates,Canada
AustraliaAustralia
Brazil, various Central and South American countriesBrazil,variousCentralandSouthAmericancountries
Certifications/PatentsCertifications/Patents
US FDA 510(k) Clearance: Obtained regulatory approval for key products such as HELIOS, LOTUS III, PicoLO, and PALLAS PREMIUM for market entry in the United States.USFDA510(k)Clearance:ObtainedregulatoryapprovalforkeyproductssuchasHELIOS,LOTUSIII,PicoLO,andPALLASPREMIUMformarketentryintheUnitedStates.
European CE Mark: Acquired unified conformity certification for products like HELIOS, LOTUS III, PicoLO, and PALLAS for sales in the European market.EuropeanCEMark:AcquiredunifiedconformitycertificationforproductslikeHELIOS,LOTUSIII,PicoLO,andPALLASforsalesintheEuropeanmarket.
Japanese PMDA Approval: Obtained regulatory approval from the Pharmaceuticals and Medical Devices Agency for PicoLO and PALLAS products in Japan.JapanesePMDAApproval:ObtainedregulatoryapprovalfromthePharmaceuticalsandMedicalDevicesAgencyforPicoLOandPALLASproductsinJapan.
Brazilian ANVISA Approval: Secured regulatory approval for market entry in Brazil.BrazilianANVISAApproval:SecuredregulatoryapprovalformarketentryinBrazil.
MDSAP (Medical Device Single Audit Program) Certification: The first Korean laser company to pass the medical device quality audit system for 5 countries: USA, Canada, Japan, Australia, and Brazil.MDSAP(MedicalDeviceSingleAuditProgram)Certification:ThefirstKoreanlasercompanytopassthemedicaldevicequalityauditsystemfor5countries:USA,Canada,Japan,Australia,andBrazil.
Technology Patents: Holds patents for proprietary laser technologies, including PicoLO's DOE fractional technology and HELIOS III's RTP (Real Twin Pulse) technology.TechnologyPatents:Holdspatentsforproprietarylasertechnologies,includingPicoLO'sDOEfractionaltechnologyandHELIOSIII'sRTP(RealTwinPulse)technology.
Awards: Received numerous technology and export-related awards, including the '2020 Industrial Technology Award of the Month' (PicoLO), 'Korea Technology Award' (PicoLO), '20 Million Dollar Export Tower' (2024), 'Global Hidden Champion' designation, 'Next-Generation World-Class Product' selection (PicoLO, PicoLO PREMIUM, HELIOS IV 785 PICO), and 'Technology Innovation Award' (HELIOS IV 785).Awards:Receivednumeroustechnologyandexport-relatedawards,includingthe'2020IndustrialTechnologyAwardoftheMonth'(PicoLO),'KoreaTechnologyAward'(PicoLO),'20MillionDollarExportTower'(2024),'GlobalHiddenChampion'designation,'Next-GenerationWorld-ClassProduct'selection(PicoLO,PicoLOPREMIUM,HELIOSIV785PICO),and'TechnologyInnovationAward'(HELIOSIV785).